Novartis NVS recently held an investor event, wherein management projected sales to grow at a compounded annual growth rate ...

Through the Entresto scientific program, we are reimagining the standard of care for HFrEF patients and the use of Entresto as foundation therapy." Patients with heart failure who need to be admitted ...

Novartis recently announced positive Phase III results from its KALUMA study of GanLum (ganaplacide/lumefantrine), a new ...

EAST HANOVER, N.J., Sept. 2, 2019 /PRNewswire/ -- Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function ...

As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indication—but there were some signs of hope. Now, a new Entresto study is again ...

Novartis last year launched an unbranded campaign called Understanding Heart Failure. Novartis’ new heart-failure drug Entresto generated $21 million in sales in 2015, and the company attributed the ...

Novartis now looks almost certain to pocket an important first-in-class approval for blockbuster heart drug Entresto, despite trial data that, at least on the surface, spelled failure for the drug. An ...

The Phase 4, randomized, open-label, parallel-group TRANSITION study (N=1002) evaluated the safety and tolerability of Entresto in HFrEF patients after they were stabilized following an acute heart ...

Medicare covers a variety of generic and brand-name prescription drugs, including Entresto, to treat heart failure. Entresto is a brand-name prescription medication containing sacubitril and valsartan ...

Novartis announced the publication of clinical data from a post-hoc analysis showing significant improvement in physical and social activities at 8 months with ...

Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...